Wixela Inhub is the first approved generic version of Advair Diskus. It is therapeutically equivalent to Advair Diskus.
Wixela Inhub and Advair Diskus (fluticasone propionate and salmeterol inhalation powder, USP) are combination products containing a corticosteroid and a long-acting beta2-adrenergic agonist indicated for:
- Twice-daily treatment of asthma in patients aged 4 years and older.
- Maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD).
Wixela Inhub and Advair Diskus are NOT indicated for relief of acute bronchospasm.
Both Wixela Inhub and Advair Diskus are supplied as inhalers containing powder for inhalation in the following strengths:
- fluticasone propionate 100 mcg and salmeterol 50 mcg
- fluticasone propionate 250 mcg and salmeterol 50 mcg
- fluticasone propionate 500 mcg and salmeterol 50 mcg
Advair Diskus was first approved by the FDA in August 2000.
Wixela Inhub was first approved by the FDA in January 2019.
Generic products in general provide significant cost savings compared to the brand name product.
For more information on pricing see:
- Wixela Inhub Prices, Coupons and Patient Assistance Programs
- Advair Diskus Prices, Coupons and Patient Assistance Programs